Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Pharmalittle: We're reading about a troubled Novo manufacturing plant, PEPFAR funding and more news

Summary by STAT
Gilead Sciences subsidiary Kite Pharma acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million

1 Articles

STATSTAT
Center

Pharmalittle: We're reading about a troubled Novo manufacturing plant, PEPFAR funding and more news

Gilead Sciences subsidiary Kite Pharma acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million

·Boston, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

STAT broke the news in Boston, United States on Friday, August 22, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Gilead Sciences icon

Gilead Sciences

United States icon

United States

News
For You
SearchBlindspotLocal